International Stem Cell Corp. (ISCO) Initiates Final Step to File IND for Treatment of Parkinson’s Disease
International Stem Cell, a biotech company focused on developing novel stem cell-based therapies, has initiated its IND-enabling pharmacology and toxicology non-human primate studies directed by Yale School of Medicine Professor D. Eugene Redmond Jr. MD, an internationally recognized neurosurgeon and a leader in the use of stem cells for the treatment of Parkinson's disease. The studies will assess the safety and efficacy of ISCO’s proprietary stem cell-derived neuronal cells when administered to non-human primates with moderate to severe Parkinson's disease symptoms. Established endpoints of these multi-dose studies are to determine cell fate, biodistribution, and primate behavioral evaluations using a standardized…